SCHEMBL4773595

SCHEMBL4773595

Cc1ccc(Cl)cc1N1CCN(C(c2cncn2C)C(N)C=O)CC1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
NPSR1 Q6W5P4 4/20 0.41
HTT P42858 3/20 0.41
ATM Q13315 1/20 0.41
USP2 O75604 2/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
MCOLN3 Q8TDD5 1/20 0.39
RPS6KB1 P23443 2/20 0.39
MAPT P10636 3/20 0.38
LMNA P02545 3/20 0.38
TSHR P16473 3/20 0.38
KDM4E B2RXH2 1/20 0.37
GAA P10253 1/20 0.37
POLB P06746 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4771297 0.79 NPSR1 (0.46) ALDH1A1NPSR1HTTATMUSP2
SCHEMBL4776952 0.78 LMNA (0.46) ALDH1A1NPSR1HTTUSP2MEN1
SCHEMBL4776587 0.76 KDM4E (0.45) ALDH1A1NPSR1HTTUSP2MEN1
SCHEMBL4779189 0.76 NPSR1 (0.43) ALDH1A1NPSR1USP2MEN1KMT2A
SCHEMBL4776309 0.75 NPSR1 (0.42) ALDH1A1NPSR1HTTUSP2MEN1
SCHEMBL4770304 0.72 NPSR1 (0.39) ALDH1A1NPSR1HTTATMUSP2
SCHEMBL4794152 0.70 USP2 (0.49) ALDH1A1NPSR1HTTUSP2MEN1
SCHEMBL4778604 0.68 NPSR1 (0.46) ALDH1A1NPSR1HTTATMUSP2
SCHEMBL4775611 0.68 NPSR1 (0.45) ALDH1A1NPSR1HTTUSP2MEN1
SCHEMBL11955709 0.67 NPSR1 (0.59) ALDH1A1NPSR1HTTUSP2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996550-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES Novartis AG (CH) 2008-12-03 EP claimed
WO-2007038459-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES NOVARTIS AG (CH) 2007-04-05 WO claimed